Oxicams: Metabolic Disposition in Man and Animals

References

• Fenner H. Comparative biochemical pharmacology of the oxicams. Scand. J. Rheum. 1987; Suppl 65: 97–101
   Google Scholar
• Folco G., Borghi C., Berti F. Nonsteroidal antiinflammatory drug therapy: Advantages and disadvantages of long half-life drugs versus slow-release formulations. Int. Clin. Pharm. Res. 1986; 6: 475–480
   PubMed Web of Science ®Google Scholar
• Whitehouse M. W. Oxicams: Relative safety and anti-injury effects in rats. Br. J. Clin. Pharmac. 1986; 22: 111s–116s
   PubMed Web of Science ®Google Scholar
• Wiseman E. H., Chiaini J. Antiinflammatory and pharmacokinetic properties of sudoxicam N- (2-thiazolyl)-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide. Biochem. Pharmacol. 1972; 21: 2323–2334
   PubMed Web of Science ®Google Scholar
• Hobbs D. C., Twomey T. M. Metabolism of piroxicam by laboratory animals. Drug Metab. Dispos. 1981; 9: 114–118
   PubMed Web of Science ®Google Scholar
• Fenner H. Pharmacokinetics of piroxicam: New aspects. Eur. J. Rheum. Inflam. 1987; 9: 42–48
   Google Scholar
• Borondy P. E., Michniewicz B. M. Metabolic disposition of isoxicam in man, monkey, dog, and rat. Drug Metab. Dispos. 1984; 12: 444–451
   PubMed Web of Science ®Google Scholar
• Gonzalez J. P., Todd P. A. Tenoxicam: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987; 34: 289–310
   PubMed Web of Science ®Google Scholar
• Francis R. J., Allen J. G., Looi D., Dixon J. S., Bird H. A., Wright V. Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. Eur. J. Drug Metab. Pharmac. 1987; 12: 59–63
   PubMed Web of Science ®Google Scholar
• Hobbs D. C., Twomey T. M. Metabolism of sudoxicam by the rat, dog, and monkey. Drug Metab. Dispos. 1977; 5: 75–81
   PubMed Web of Science ®Google Scholar
• Wiseman E. H., Chang Y., Hobbs D. C. Interaction of sudoxicam and aspirin in animals and man. Clin. Pharmacol. Ther. 1975; 18: 441–448
   PubMed Web of Science ®Google Scholar
• Rowland M., Tozer T. N. Clinical Pharmacokinetics Concepts and Applications. Lea and Febiger, Philadelphia 1980; 254
   Google Scholar
• Chatfield D. H., Hunter W. H. The metabolism of acetamidothiazoles in the rat: 2-acetamido-, 2-acetamido-4-methyl-, and 2-aceta- mido-4-phenylthiazole. Biochem. J. 1973; 134: 869–878
   PubMed Web of Science ®Google Scholar
• Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Piroxicam: A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292–323
   PubMed Web of Science ®Google Scholar
• Hobbs D. C., Twomey T. M. Piroxicam pharmacokinetics in man: Aspirin and antacid interaction studies. J. Clin. Pharmacol. 1979; 19: 270–281
   PubMed Web of Science ®Google Scholar
• Twomey T. M., Hobbs D. C. Biotransformation of piroxicam in man. Fed. Proc. 1978; 37: 271
   Google Scholar
• Lambardino J. G. Synthesis and antiinflammatory activity of metabolites of piroxicam. J. Med. Chem. 1981; 24: 3942
   Google Scholar
• Hobbs D. C. Piroxicam pharmacokinetics: Recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects. Am. J. Med. 1986; 81(B)22–28
   PubMedGoogle Scholar
• Richardson C. J., Blocka L. N., Ross S. G., Verbeeck R. K. Effects of age and sex on piroxicam disposition. Clin. Pharmacol. Ther. 1985; 37: 13–18
   PubMed Web of Science ®Google Scholar
• Guentert T. W., Defoin R., Mosberg H. Accelerated elimination of tenoxicam and piroxicam by cholestyramine. J. Clin. Pharm. 1988; 43: 179
   Web of Science ®Google Scholar
• Edwards I. R., Ferry D. G., Campbell A. J. Factors affecting the kinetics of two benzothiazine nonsteroidal antiinflammatory medicines, piroxicam and isoxicam. Eur. J. Clin. Pharmacol. 1985; 28: 689–692
   PubMed Web of Science ®Google Scholar
• Woolf A. D., Rogers H. J., Bradbrook I. D., Corless D. Pharmacokinetic observations on piroxicam in young adult, middle-aged, and elderly patients. Br. J. Clin. Pharmac. 1983; 16: 433–437
   PubMed Web of Science ®Google Scholar
• Mailhot C., Dahl S. L., Ward J. R. The effect of cimetidine on serum concentrations of piroxicam. Pharmacotherapy 1986; 6: 112–117
   PubMed Web of Science ®Google Scholar
• Dipasquale G., Rassaert C., Richter R. The antiinflammatory properties of isoxicam 4-hydroxy-2-methyl-1-N-5-methy 1-3-isoxlyl-2H-1, 2-benzothiazine-3-carboxarnide-1, 1-dioxide. Agents Actions 1975; 5: 256–263
   PubMedGoogle Scholar
• Gowans J. D.C. Placebo-controlled multicenter studies in the treatment of rheumatoid arthritis and degenerative joint disease. Semin. Arthritis Rheumatism 1982; 12 Suppl 2: 160–164
   Web of Science ®Google Scholar
• Fogari R., Bonebrake R. A. Aspirin and placebo-controlled study of isoxicam in the treatment of rheumatoid arthritis. Semin. Arthritis Rheumatism 1982; 12, Suppl 2: 165–169
   Web of Science ®Google Scholar
• Downie W. W. Comparative studies of isoxicam in rheumatoid arthritis. Semin. Arthritis Rheumatism 1982; 12, Suppl 2: 170–174
   Web of Science ®Google Scholar
• Kolle E. U., Vollmer K. O. Pharmacokinetics of isoxicam in man following oral administration. Arzneim. Forsch. 1983; 33: 582–586
   PubMed Web of Science ®Google Scholar
• Borondy P. E., Michniewicz B. M., Eiseman I., Yakatan G. J. Metabolic disposition of isoxicam-14C in man and in the rat. Pharmacologist 1981; 23: 212
   Google Scholar
• Michniewicz B. M., Yakatan G. J., Borondj P. E. Metabolic disposition of isoxicam-14C in beagle dogs. Pharmacologist 1982; 24: 95
   Google Scholar
• Ferry N., Cuisinaud G., Ouzan D., Trepo C., Sassard J. Pharmacokinetics of isoxicam in hepatic disease. Br. J. Clin. Pharmac. 1986; 22: 143S–147S
   PubMed Web of Science ®Google Scholar
• Esquivel M., Ogilvie R. I., East D. S., Shaw D. H., Heathcote J. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis. Clin. Invest. Med. 1987; 10: 363–367
   PubMed Web of Science ®Google Scholar
• Caillé G., Lariviere Y., Lacasse Y., Vezina M., Besner J. G. The effect of administration of propranolol on the pharmacokinetics of isoxicam. Biopharm. Drug Dispos. 1986; 7: 63–69
   PubMed Web of Science ®Google Scholar
• Farnham D. J. Studies of isoxicam in combination with aspirin, warfarin sodium and cimetidine. Semin. Arthritis Rheumatism 1982; 12, Suppl 2: 179–183
   Web of Science ®Google Scholar
• Caillé G. Isoxicam: Interactions with other drug regimens in Non-steroidal Anti-inflammatory Agents in the Elderly, B. Amor. EULAR, Basel 1984; 106–113
   Google Scholar
• Bury R. W., Whitworth J. A., Saines D., Kincaid-Smith P., Moulds R. F.M. Effect of impairment of renal function on the accumulation and disposition of isoxicam, Eur. J. Clin. Pharmacol. 1985; 28: 585–588
   Web of Science ®Google Scholar
• Brooks P. M., McCredie M., Prowse M., Podgorski M., Forrest M., Munro I., Boutagy J., Pei-Ling L. Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. Pharmatherapeutica 1986; 4: 665–672
   PubMedGoogle Scholar
• Campbell A. J., Ferry D. G., Edwards I. R. Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects. Br. J. Rheum. 1985; 24: 176–178
   PubMedGoogle Scholar
• Woolf T. F., Black A., Chang T. In vivo metabolism of isoxicam in rat, dog, and monkey. Drug Metab. Dispos., In press.
   Web of Science ®Google Scholar
• Woolf T. F., Black A., Chang T. In vitro metabolism of isoxicam by horseradish peroxidase. Xenobiotica, In press.
   Web of Science ®Google Scholar
• Ichihara S., Tomisawa H., Fukazawa H., Tateishi M., Joly R., Heintz R. Involvement of leukocytes in the oxygenation and chlorination reaction of phenylbutazone. Biochem. Pharmacol. 1986; 35: 3935–3939
   PubMed Web of Science ®Google Scholar
• Ichihara S., Tomisawa H., Fukazawa H., Tateishi M. Involvement of leukocyte peroxidases in the metabolism of tenoxicam. Biochem. Pharmacol. 1985; 34: 1337–1338
   PubMed Web of Science ®Google Scholar
• Bird H. A., Hill J., Dixon J. S., Looi D., Wright V. A double-blind, parallel study of tenoxicam and piroxicam in patients with osteoarthrosi s. Curr. Med. Res. Opin. 1985; 9: 529–535
   PubMed Web of Science ®Google Scholar
• Heintz R. C., Guentert T. W., Enrico J. F., Dubach U. C., Brandt R., Jeunet F. S. Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheum. Inflam. 1984; 7: 33–44
   PubMedGoogle Scholar
• Horber F. F., Guentert T. W., Weidekamm E., Heizmann P., Descoeudres C., Frey F. J. Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur. J. Clin. Pharmacol. 1986; 29: 697–701
   PubMed Web of Science ®Google Scholar
• Bird H. A., Francis R. J., Le Gallez P., Hill J., Dixon J. S., Allen J. G., Wright V. Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. Eur. J. Rheum. Inflam. 1985; 8: 60–69
   PubMed Web of Science ®Google Scholar
• Francis R. J., Dixon J. S., Lowe J. R., Harris P. A. The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. Eur. J. Drug Metab. Pharmac. 1985; 10: 309–314
   PubMed Web of Science ®Google Scholar
• Guentert T. W., Schmitt M., Defoin R. Acceleration of the elimination of tenoxicam by cholestryamine in the dog. J. Pharmacol. Exp. Ther. 1986; 238: 295–301
   PubMed Web of Science ®Google Scholar
• Ichihara S., Tsuyuki Y., Tomisawa H., Fukazawa H., Nakayama N., Tateishi M. Metabolism of tenoxicam in rats. Xenobiotica 1984; 14: 727–739
   PubMed Web of Science ®Google Scholar
• Ichihara S., Ichihara Y., Nakayama S., Tomisawa H., Fukazawa H., Suzuki T., Tateishi M. Metabolic fate of tenoxicam and a possible mechanism of anti-inflammoratory activity. J. Pharmacobio-Dyn. 1985; 8: S-158
   Google Scholar
• Dell D., Joly R., Meister W., Arnold W., Partos C., Guldimann B. Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its metabolite, in human urine. J. Chromatogr. 1984; 317: 483–492
   PubMed Web of Science ®Google Scholar
• Tamimura H., Mukaihara S., Mine Y., Yotsumoto F. Bilary excretion of tenoxicam in cholecystectomized patients. Arch. Jpn. Chir. 1984; 53: 779–785
   PubMedGoogle Scholar